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Following the 2009 H1N1 pandemic and ongoing sporadic avian-to-human transmission of H5N1 viruses, an emphasis has been
placed on better understanding the determinants and pathogenesis of severe inﬂuenza infections. Much of the current literature
has focused on viral genetics and its impact on host immunity as well as novel risk factors for severe infection (particularly within
the H1N1 pandemic). An understanding of the host genetic determinants of susceptibility and severe respiratory illness, however,
is currently lacking. By better deﬁning the role of genetic variability in inﬂuenza infection and identifying key polymorphisms that
impairthehostimmuneresponseorcorrelatewithprotection,wewillbeabletobetteridentifyat-riskpopulationsandnewtargets
fortherapeuticinterventionsandvaccines.Thispaperwillsummarizeknownimmunogeneticfactorsassociatedwithsusceptibility
or severity of both pH1N1 and H5N1 infections and will also identify genetic pathways and polymorphisms of high relevance for
future study.
1.Introduction
Transmission of zoonotic inﬂuenza A viruses to humans
is commonly the cause of new pandemics, which typically
result in high disease burden and increased symptomatic
severity and mortality. In order to predict which populations
may be at highest risk of infection and to develop more
eﬀective therapeutic interventions and vaccines, a thorough
understanding of both viral and host contribution to
pathogenesis is required. In both the recent 2009 H1N1
(pH1N1) pandemic and the on-going rare avian-to-human
transmission of H5N1, numerous studies have taken an in-
depth look at the impact of viral evolution and mutation on
viral pathogenesis. Conversely, while both human and ani-
mal model studies of the host immune response to infection
have identiﬁed correlates of severe disease, the contribution
of host genetics to these correlates and to variability in
susceptibility remains relatively unknown. Identiﬁcation of
host genetic polymorphisms contributing to altered suscep-
tibility or disease severity has several beneﬁts: identiﬁcation
of high-risk populations at greater need of prophylactic
intervention, elucidation of host proteins important in
virus-host interactions, and new targets for therapeutic
interventions or vaccine development [1]. Studies of host
genetics have provided important contributions to the study
of other infectious diseases, including HIV, SARS, and HCV.
This paper will describe what is currently known about the
impact of host immunogenetics in both pH1N1 and H5N1
infections and will identify highly relevant polymorphisms
and genetic pathways that could be investigated in future
work.
2. 2009 Pandemic H1N1
H1N1 inﬂuenza viruses emerged as a result of a presumed
or documented reassortment of segments from viruses of
zoonoticoriginwithhuman-adaptedinﬂuenzavirustocause
pandemic spread in 1918 and again in 2009. The 2009
appearance of a swine-origin reassortant virus led to the
ﬁrst pandemic of the 21st century. During earlier pandemics,
records indicate that certain individuals or populations
appeared to be more susceptible to severe disease, but the2 Clinical and Developmental Immunology
abilitytoconductstudiesinordertounderstandtheimmune
mechanisms that underlay the increased propensity for
complications was limited. The 2009 H1N1 (pH1N1) pan-
demic was accompanied by improved surveillance, thereby
facilitating better estimation of disease severity and methods
to examine the immune mechanisms behind complicated
disease [2–11]. This surveillance allowed for the identiﬁca-
tion of several novel risk factors among various populations,
butwithalimitedunderstandingofthegeneticvariationthat
may contribute to those risk factors.
2.1. Novel Risk Factors Associated with Severity of Pandemic
H1N1 Infection. The 1918 H1N1 as well as the recent 2009
pandemics were both notable for the comparatively high
rates of morbidity among healthy, young adults not typically
observed with seasonal inﬂuenza [11]. During the recent
pandemic, several studies of conﬁrmed pH1N1 cases in
Canada and the US reported the median age of severe
infections to be 23–27 years old [8, 10]. In Canada, 30%–
48% of infections also presented in persons with comorbidi-
ties; diabetes, heart disease, and immunosuppression were
associated with the highest risk of severe infection, while
lung diseases and obesity were among the most common
underlying conditions [10, 12–14] .T h er o l eo fp r e g n a n c ya s
a risk factor, regardless of the stage, was also supported by
a myriad of reports; among hospital admissions, pregnancy
accounted for roughly 30% of female cases aged 20–39 years
old [9, 12, 15].
Ethnicity was another major risk factor of pH1N1 sus-
ceptibilityidentiﬁedinseveralpopulationsinNorthAmerica
and Australasia. The increased proportion of aboriginal
individuals presenting with severe pH1N1 infection was
not unique for this pandemic and was also seen in the
1918 H1N1 pandemic during which mortality in aboriginal
communities in North America (3%–9%) was signiﬁcantly
higher than among nonaboriginal communities [16, 17]. In
the 2009 pandemic, Paciﬁc Islanders accounted for 2.5% of
the Australian population but made up 9.7% of patients
admitted to Australian ICUs with conﬁrmed pH1N1. Maori
individuals represent 13.6% of the New Zealand population,
but accounted for 25% of ICU admissions in the ANZIC
study [18]. Kumar et al. [12] also reported 25.6% of
the individuals admitted to ICUs in Canada belonged to
First Nations, Inuit, Metis, or aboriginal ethnicities; this is
an overrepresentation compared to the 4.4% rate of self-
reported aboriginal ethnicity according to the 2001 census
(Statistics Canada). Similarly, pH1N1 mortality rates among
American-Indian/AlaskaNativeswerefourtimeshigherthan
persons in all other ethnic populations combined in the
United States [19].
None of these studies examined the causal factors that
lead to the higher inﬂuenza mortality in the high-risk groups
described. It is clear that multiple converging risks account
for the high rates of complications, including socioeconomic
factors such as inability to access care, delayed seeking
of care, higher rates of poverty, and greater numbers of
household members. A few of the risk factors listed in
the previous sections, however, share a degree of immune
system impairment. One can, therefore, speculate that the
partial protection aﬀorded by the immune system, primarily
by cross-reactive CD8+ T-cells recognizing viral epitopes,
is decreased in some of the previously described groups
(pregnancy is a good example). Additionally, genetic vari-
ation in immune-related genes leading to either gain-of-
function or loss-of-function phenotypes could contribute to
the variation observed in pH1N1 susceptibility and disease
severity.
2.2. Novel Immunogenetic Risk Factors Associated with Sever-
ity of Pandemic H1N1 Infection. When a novel strain of
inﬂuenzaemerges,thepre-existingantibodyresponsedirect-
ed largely at the surface glycoproteins is rendered ineﬀective.
In these cases, the mechanisms underlying heterosubtypic
cross-protection assume a dominant role and it is, therefore,
not surprising that immune dysfunction caused by underly-
ing genetic polymorphisms may lead to impaired responses
and would, therefore, be associated with adverse outcomes.
During the 2009 H1N1 pandemic, several immunogenetic
determinants of severe disease were identiﬁed.
When a novel strain of inﬂuenza emerges, the pre-
existing antibody response directed largely at the surface gly-
coproteins is rendered ineﬀective. In these cases, the mech-
anisms underlying heterosubtypic cross-protection assume
a dominant role and it is, therefore, not surprising that
immune dysfunction caused by underlying genetic polymor-
phisms may lead to impaired responses and would therefore
be associated with adverse outcomes. During the 2009 H1N1
pandemic, several immunogenetic determinants of severe
disease were identiﬁed.
2.2.1. CCR5Δ32 Allele. The CCR5 protein is a chemokine
receptor expressed primarily on T cells, macrophages, and
dendritic cells. CCR5 plays a pivotal role in mediating
leukocyte chemotaxis in response to chemokines (including
RANTES, MIP-1α,a n dM I P - 1 β) and is believed to be impor-
tant in the homing of many immune cell subsets, including
regulatory T cells and Th17 cells, to mucosal surfaces. Until
recently, the purported role of CCR5 in supporting the
antiviral immune response was limited to appreciation of the
eﬀectofreceptordeﬁciencyinprotectingfromHIVinfection
and disease progression among individuals homozygous for
the Δ32 allele. The understanding of the roles played by
CCR5 was expanded when the Δ32 allele was found to
be associated with an increased risk of symptomatic and
fatal West Nile Virus (WNV) infection [20–22] ,as e v e r e
adverse reaction to the live yellow fever virus vaccine,
and with severe tick-borne encephalitis symptoms [23, 24].
Together, these data suggest that CCR5 may also play a
critical role in the immune response to ﬂavivirus infections.
The spectrum of symptomatic severity observed during
the 2009 H1N1 pandemic led our group to study CCR5
genotype among patients requiring intensive care admission
and respiratory support for severe H1N1 symptoms. Among
twenty samples of conﬁrmed severe pH1N1 infection, the
CCR5Δ32 allele was found in 5 out of 9 of the Caucasian
individuals, giving a Caucasian allele frequency of 27.8%
[25]( Table 1). This observed frequency is approximately 2.5Clinical and Developmental Immunology 3
Table 1: Genetic polymorphisms of interest in H1N1 susceptibility and severity.
Gene Polymorphism Functional signiﬁcance Reference
CCR5 CCR532 Increased allele frequency among Canadian H1N1 ICU cases [25]
FcγRIIa,
IGHG2
IGHG2 ∗n/∗-n
FcγRIIa-R131H
Polymorphisms previously linked to IgG2 deﬁciency, but not
corroborated in H1N1 patients [28–30]
NLRP3
2107C/A (Q705K)
rs4612666 (intron 7)
rs10754558 (3  UTR)
Association with dysregulation of inﬂammatory response (2107),
alteration of NLRP3 mRNA stability and enhancer activity [33, 34]
HLA Various alleles Inﬂuenza-speciﬁc CTL responses exhibit varying frequency and
magnitude across various HLA alleles [35]
times higher than that reported for local North American
Caucasian populations [26, 27]. Given the small sample size
available in this cohort, further studies will be required to
conclusively determine the impact of CCR5 deﬁciency on
pH1N1 susceptibility and severity.
2.2.2. IgG2 Subclass Deﬁciency. Similarly to IgG1, IgG2a and
IgG2b are able to bind to Fc receptors with high aﬃnity and
are thought to be important in protecting against inﬂuenza
infection. A group of Australian investigators identiﬁed
an index case of severe inﬂuenza in a pregnant woman
with IgG2 subclass deﬁciency and subsequently measured
total IgG and IgG subclasses in all patients with pH1N1
infection requiring ICU care (many of whom were pregnant)
compared to less severe controls and asymptomatic pregnant
womenpresentingtoantenatalclinic.AlowlevelofIgG2was
correlated with severe pH1N1 infection after multivariate
analysis. Measurement of IgG2 after 90 days among 15 of the
surviving IgG2-deﬁcient patients showed that 11 remained
IgG2 deﬁcient despite albumin levels returning to baseline
values [28]. Additionally, a case-control study from China
enrolled 38 Asian patients with respiratory failure due to
severe pandemic inﬂuenza and compared IgG2 levels with
36 mild cases. They did not ﬁnd any cases of selective
IgG2 deﬁciency, but did observe signiﬁcantly lower levels
of IgG2 among the severe cases (despite normal levels of
the other IgG subclasses) [29]. The authors looked for the
presence of FcγRIIa and IGHG2 genotypes (Table 1) that
were previously shown to be associated with IgG2 deﬁciency,
but found similar rates among cases and controls. They did,
however, corroborate the previously reported ﬁnding [30]
of cytokine dysregulation among severe cases of infection
and suggested that the mechanism responsible for the low
IgG2 is the more robust Th1 response and a suppressed Th2
response. Given the lack of FcγRIIa and IGHG2 genotype
data available from the Gordon et al. study [28], the impact
of these polymorphisms on IgG2 levels and severe pH1N1
infection remains to be determined.
2.3. Additional Candidate Polymorphisms Contributing to
Severe Inﬂuenza. Genetic polymorphisms associated with
pH1N1 susceptibility and disease severity identiﬁed to date
are limited, and much of the data is derived from small
cohorts. An improved understanding of the sequence of
immune responses to inﬂuenza as well as the application of
newer technologies that employ high-throughput expression
arrayorsequencingtechnologiescanbeusedtoguideamore
focused approach to identify speciﬁc pathways that may be
diﬀerentially activated by individuals with severe disease.
Based on available data, we can identify several immune
pathways and their genetic variants that warrant further
investigation.
2.3.1. NLRP Inﬂammasomes. Recently, emphasis has been
givento therole of the inﬂammasome inviral infections and,
speciﬁcally, inﬂuenza. NLRP3 (NOD-like receptor family,
pyrin domain-containing 3) inﬂammasomes are multipro-
tein complexes containing NLRP3, ASC (or Pycard), and
caspase 1. Activation of cytokine/chemokine release through
NLRP3 requires a signal derived from Toll-like receptor
(TLR) stimulation, with resultant production of pro-IL-1β,
-IL-18, and -IL-33. The prointerleukins are in turn cleaved
to their respective active forms by caspase 1, which requires
the input of an additional signal. The second signal in the
context of inﬂuenza has been elegantly demonstrated by
Ichinohe et al. [31], who showed that golgi-localized H1N1
M2 is both necessary and suﬃcient to trigger inﬂammasome
activation. Diﬀerential expression of the components of the
two signaling cascades that are required for inﬂammasome
activation may therefore explain diﬀerences in inﬂuenza
disease severity. Indeed, mouse knockout studies have shown
that intact inﬂammasomes are necessary for innate immune
responses to inﬂuenza A, chemokine production, and late
stage viral clearance (reviewed in [32]). Evidence suggests
that NLRP3-mediated signaling is also important in cellular
recruitment and tissue repair during infection. A similar
requirement for proper ASC function was observed in adap-
tiveinﬂuenzaimmuneresponses.MultipleNLRP3SNPshave
been associated with dysregulated inﬂammation responses
and NLRP3 mRNA stability in humans but have not been
examinedinthecontextofpH1N1susceptibilityormortality
[33, 34]( Table 1).
2.3.2. HLA Alleles. The CD8+ T-cell response is a strong
predictor of vaccine-induced protection and is thought to
be particularly valuable in the elderly. Because this response
is focused on more conserved viral proteins, it has the
additional beneﬁt of providing some cross-reaction with
new inﬂuenza strains [46, 47]. Undoubtedly, multiple factors
underlie the diﬀerences in disease severity among ethnic4 Clinical and Developmental Immunology
groups, as previously discussed. From an immunogenetic
perspective, however, HLA alleles are among the most vari-
able human genes, and it is therefore conceivable that vari-
able proportions of HLA class I alleles among ethnic groups
may lead to qualitatively and quantitatively distinct CD8+
T-cell responses, as well as diﬀerences in immunodominant
epitopes (Table 1). Boon et al. [35] have demonstrated that
the frequency of CTL responses speciﬁc for the HLA-B8-
restricted epitope NP380–388 was lower in HLA-B27-positive
donors than in HLA-B27-negative donors. They also showed
that the HLA-A1-restricted epitope NP44–52 responses were
higher in HLA-A1-, -A2-, -B8-, and -B35-positive donors
than in other donors. These observations suggest that the
epitope speciﬁcity and magnitude of the CTL response is
related to the HLA class I genetic background [35].
2.3.3. Gene Expression Studies. T h er o l eo fc e l l - m e d i a t e di m -
munity in ameliorating infection caused by novel inﬂuenza
strains has been the focus of intense study [48] and it is,
therefore, the most compelling area to investigate in order
to identify immunogenetic factors that predict severity of
pandemic H1N1 inﬂuenza. A comprehensive investigation
was undertaken by Bermejo-Martin et al. [49] in a study
from Spain. They enrolled 19 critically ill patients with
primary pH1N1 inﬂuenza pneumonia and used gene expres-
sion analysis in order to identify host immune responses
associated with severe disease deﬁned by illness requiring
mechanical ventilation. They identiﬁed impaired expression
of a number of MHC class II and MHC class I genes,
T-cell receptor-associated genes, and also of a cluster of
genes thought to be involved in dendritic cell maturation,
indicating defective antigen presentation in the most severe
group of patients. They found further evidence for the
eﬀect of altered antigen presentation on the development
of an appropriate adaptive response against the virus in
the impaired expression of a group of genes critical to the
a c t i v a t i o na n df u n c t i o no fb o t hTa n dBc e l l s .T h eg r o u p
with severe illness also showed higher expression of genes
involved in IL-6 and IL-10 pathways, and these results were
in concordance with the high serum levels of IL-6 and IL-
10 in the group dependant on mechanical ventilation. The
authors concluded that severe disease is associated with an
impaired transition from innate to adaptive immunity in
response to the pH1N1 virus, similar to observations in the
context of SARS and severe infections caused by H5N1. The
impaired adaptive response was also associated with delayed
viral clearance. This study did not, however, explore the role
of genetic polymorphisms in this immune dysregulation.
3. H5N1 AvianInﬂuenza
Pathogenic avian inﬂuenza A/H5N1 viruses are endemic
among poultry populations across Asia and Africa and
presentanongoingriskforavian-to-humantransmission.As
of June 22, 2011, the WHO reports a total of 562 conﬁrmed
H5N1 cases and 329 deaths across 15 countries worldwide
[50]. Although human-to-human transmission of H5N1 has
so far been rare, the potential for viral evolution into a more
transmissible strain raises the possibility that H5N1viruses
could cause a pandemic. Given the high mortality rate
currentlyassociatedwithhumanH5N1infection,athorough
understanding of the immune response and the underlying
mechanisms of viral pathogenesis is crucial to improve
treatment and to identify highly susceptible populations.
To date, much of the research into the immunobiology
and pathogenesis of human H5N1 infection has focused
on the H5 haemagglutinin protein and the impact of viral
genetic polymorphisms on viral pathogenicity. Although
studies have begun to characterize of the role of the host
immune response in pathogenesis, the impact of genetic
variability on susceptibility and disease severity remains an
important gap in our current knowledge. By identifying host
genetic polymorphisms that exacerbate immunopathology
or provide protection, we will be able to improve treatment
and future vaccines [1, 51].
3.1. The Case for Host Genetic Variation in H5N1 Suscep-
tibility and Disease Severity. The precise impact of host
geneticvariability onH5N1susceptibility remainssomewhat
controversial, given the limited case data available and the
relatively low number of published studies. A case study in
Indonesia [52] found evidence of clusters of H5N1 infection
among blood relatives that may be indicative of shared
genetic susceptibility, but the authors were unable to rule
out a shared viral exposure or altered viral pathogenesis in
any of the clusters. Similar observations in a number of
additional studies have prompted several authors to suggest
a potentially strong genetic basis for H5N1 susceptibility
[53–57]. A compilation of conﬁrmed H5N1 cases worldwide
found that, on average, 22% of cases occurred in clusters,
and only 6% of cases within the clusters were not genetically
related to other cluster members [1]. While this data does
not conclusively point to genetic variation as an important
determinant of susceptibility, it is important to note that
human-to-human transmission of H5N1 is very rare, and
therefore does not likely explain the high degree of genetic
relatedness among cases [1]. It would also be expected that
clusters of nonrelated individuals working in the poultry
industry would be more prominent than genetically related
clusters, if people are at equal risk of infection [1]. Some
studies, however, have suggested that the observed clustering
ofinfectionsamongfamiliescouldoccurduetochancealone
at the low rates of infection that are observed in H5N1
and highlight the diﬃculty in drawing conclusions from the
currently available data [58].
3.2. Candidate Genes Inﬂuencing Susceptibility. Despite the
intense research into the eﬀect of viral mutations on patho-
genesisandviralﬁtness,veryfew,ifany,studieshaveassessed
the impact of speciﬁc host polymorphisms on human
H5N1 infection. Although genetic association studies face
a number of challenges with regard to H5N1 infection,
including limited numbers of infected patients, diﬃculty in
determining appropriate control populations, and limited
human-to-human transmission with resultant high like-
lihood of exposure to unique virus, identifying genetic
variants involved in increased susceptibility and/or disease
outcome could provide important data regarding crucialClinical and Developmental Immunology 5
Table 2: Genetic polymorphisms of interest in H5N1 susceptibility and severity.
Gene Polymorphism Functional signiﬁcance References
MBL2 230G/A Low serum MBL levels; increased susceptibility to SARS [36, 37]
MxA
−88G/T (rs2071430)
−123C/A (rs17000900)
Increased basal (−123A) and IFN-stimulated (−88T) MxA expression and
activity in vitro; altered susceptibility to SARS [38, 39]
OAS1
rs2660 (3  UTR A/G)
rs3741981 (Exon 3A/G)
rs1077467 (Intron 5)
Altered susceptibility to SARS (3  UTR, Exon 3); West Nile susceptibility and
reduced activity due to splicing (Intron 5) [38, 40, 41]
CCR5 CCR532 Increased mortality among CCR5 knockout mice, increased allele frequency
among severe H1N1 infections [25, 42]
CCR2 190G/A (V64I) Altered HIV progression; stabilization of CCR2a splice variant and binding to
CCR5 [43, 44]
TLR3 908T/C Missense mutation identiﬁed in a patient with inﬂuenza-associated
encephalopathy [45]
host/virus interactions and the qualities of a protective
immuneresponse.Todate,anumberofcandidategeneshave
been identiﬁed from both human and mouse immunobiol-
ogy studies. Mouse models of inﬂuenza infection have the
advantage of being able to dissect gene expression kinetics
and the characteristics of the immune response at various
stages of infection. Comparison of infection across inbred
mouse lines demonstrates signiﬁcant diﬀerences in viral titre
and core temperature, as well as distinct patterns of immune
gene upregulation, suggesting an important contribution of
host genetic background [59].
3.2.1. Host-Virus Interactions. Genetic variation aﬀecting
host proteins required for viral entry and pathogenesis may
partially explain the sporadic and rare nature of avian-to-
human H5N1 transmission. Although humans do express
the SAα-2,3Gal molecules that are eﬃciently bound by
avian H5N1, their expression is usually limited to the lower
respiratory tract and has only occasionally been detected
in the nasal mucosa and upper respiratory tract [60, 61].
Additionally, the binding of several inﬂuenza strains to
human erythrocytes is highly variable, with up to a 40-
fold diﬀerence between individuals tested in one study,
suggesting a role for genetic polymorphism in regulating
susceptibility [62]. Whether variation in the human ST3
beta-galactosamide alpha-2,3-sialyltranferase 1 (ST3GAL1)
gene that produces the SAα-2,3Gal linkage aﬀects H5N1
susceptibility is not known, but remains a possibility [63].
Interestingly, a population genetics study designed to detect
human SNPs under virus-driven selective pressure found
a signiﬁcant enrichment of glycan biosynthesis gene SNPs
associated with viral selection, including rs3758105 (intronic
A/G SNP) in the ST3GAL1 gene [64]( Table 2). Data
demonstrating the infection of upper respiratory tract cells
with H5N1 in vitro also suggests the presence of additional
cellular receptors for the virus [61].
Alternately,preventionofviralattachmentintherespira-
tory tract is accomplished by host proteins that can sterically
hinder viral HA binding, or aggregate and opsonize the
virus. These proteins include serum mannose-binding lectin
2 (MBL2) and surfactant, pulmonary-associated protein A1
and D (SFTPA1 and SFTPD, resp.). A SNP in MBL2
(230G/A), resulting in low serum MBL levels, is associated
with SARS susceptibility [36, 37], while polymorphisms in
SFTPA1 and SFTPD are associated with other respiratory
illnesses [65, 66]( Table 2). To date, none of these poly-
morphisms have been investigated with respect to H5N1
susceptibility.
3.2.2. Innate Immune Signalling. Induction of an innate im-
mune response following infection can occur as a result
of the activation of pattern recognition receptors (PRRs),
commonly known as Toll-like receptors (TLRs). TLRs rec-
ognize many elements of foreign pathogens, including LPS,
ﬂagellin, and dsRNA, and initiate signaling cascades that
result in the production of type I interferons. Accumulating
data suggests that genetic variation in TLRs and their
associated signaling components modulates the response to
TLR ligands and, consequently, the inﬂammatory immune
response [67]. TLR3 is constitutively expressed on lung
alveolar and bronchial epithelial cells and has been shown to
contribute to the secretion of multiple cytokines following
inﬂuenza A infection [68]. Given the data suggesting that
H5N1 pathogenicity is due in part to alterations in innate
immune responses and hypercytokinemia, it is plausible that
polymorphisms altering TLR function could contribute to
susceptibilityorprotectionfrominfection.Thishypothesisis
supported by a genetic study of a case of inﬂuenza-associated
encephalopathy, a condition associated with apoptosis and
hypercytokinemia [45]. In this case, a missense mutation
(908T/C) in the TLR3 gene was identiﬁed and was shown
to be a loss-of-function mutation, suggesting a protective
role for TLR3 signaling in severe inﬂuenza infection [45]
(Table 2). Although these results are consistent with studies
suggesting a protective eﬀect of TLR3 in West Nile infection
[69], they are at odds with TLR3 null mouse studies, which
have shown reduced proinﬂammatory cytokine production
following cellular stimulation [70–72]. Consequently, the
contribution of TLR genetic variants to H5N1 inﬂammatory
responses remains to be resolved.
3.2.3. Interferon-Related Pathways. Induction of the type
I interferon response during inﬂuenza infection appears
to be important in both human and mouse models, as6 Clinical and Developmental Immunology
evidencedbytheincreasedexpressionofgenesincludingIrf1,
Iﬁ202, Oas1,a n dMx1 in mouse microarray studies [73–75]
(reviewed in [76]). This is consistent with the observation
that viral evasion and attenuation of the IFN pathway
contributes to H5N1 pathogenesis in humans and suggests
potential targets for genetic studies [75, 77]. A strong target
for analysis includes the myxovirus resistance (Mx)g e n e ,
which encodes interferon-induced antiviral proteins that
inhibit viral RNA transcription and consequently confer
inﬂuenza resistance in mouse lines with functional Mx1 alle-
les [78]. Polymorphisms in swine Mx genes have also been
associated with inﬂuenza susceptibility [79] and multiple
SNPs in the human MxA gene have been associated with
variability in IFN responsiveness in Hepatitis C infection
[80] and SARS susceptibility [38–40]( Table 2). Speciﬁ-
cally, the −123C/A promoter SNP associated with SARS
protection correlates with increased basal MxA expression,
leading the authors to speculate that −123 genotype may
be an important determinant of H5N1 susceptibility [39].
Although human MxA protein has been shown to inhibit
inﬂuenza replication [81], no studies have looked for an
association between MxA SNPs and H5N1 disease outcome
or susceptibility. Because MxA is located on chromosome 21,
studieshavecomparedsusceptibilitytorespiratoryinfections
between wild-type and trisomy 21 patients (who exhibit
increased MxA expression), but found greater susceptibility
among the trisomy 21 group [82]. This group of patients
is known to suﬀer from a multilevel T-cell dysfunction,
however, making the role of MxA in respiratory immunity
somewhat unclear.
PolymorphismsinOAS1 (2 ,5 -oligoadenylatesynthetase
1; an interferon-induced antiviral protein) have also been
associated with SARS susceptibility and progression [38, 40]
and West Nile infection [41]. Consistent with the idea of
increased H5N1 susceptibility and pathogenesis associated
with poor IFN responses, the OAS1 SNP rs1077467 is cor-
related with reduced OAS-1 protein activity and associated
with increased susceptibility to West Nile infection and in
vitro viral replication [41].
3.2.4. Cytokine Response. Comparison of severe H5N1 infec-
tions with uncomplicated seasonal inﬂuenza infections
revealed a pattern of increased viral load and elevated
cytokine production in the respiratory tract and serum [75,
83]. The robust cytokine/chemokine response often seen in
H5N1 infected patients (hypercytokinemia) is believed to be
at least partially responsible for the observed pathogenesis
and high fatality of H5N1 infection. Elevated cytokines
both in vivo and in vitro include IFNγ, sIL-2R, IL-6, IP-
10, TNFα,a n dM C P - 1[ 75, 84–86]. Mouse models of H5N1
infection also demonstrate elevated levels of MCP-1, MIP-
1α,I L - 6 ,a n dI F N γ, even compared to 1918 H1N1 virus
infection [87]. Knocking out IL-1R in mice exacerbates
H5N1pathologyandsuggeststhatIL-1β-mediatedsignalling
may be important in protection [75]. In ferret models, IP-10
upregulation and signaling through CXCR3 was determined
to be a major component of H5N1 disease severity and
mortality [88]. Expression of many of these chemokines and
cytokinesinhumansismodulatedbySNPsintheirpromoter
regions, including MCP-1 −2518 G/A [89], IP-10 −201G/A
[90], and IL-6 −174G/C [91]. Genetic variants aﬀecting
expression and function of chemokine receptors may also
modulate inﬂuenza pathogenesis, as CCR5 knock-out mice
exhibit increased inﬂuenza mortality, whereas CCR2 knock-
out strains show increased survival (Table 2); both of these
eﬀects appear to be related to the kinetics and strength of
macrophage recruitment to the lung [42]. In vitro evidence
further suggests upregulation of CCR5 on monocyte-derived
macrophages that may enhance pathogenesis [92].
4. Conclusions
Although relatively few studies have systematically evaluated
theinﬂuenceofgeneticpolymorphismsonsusceptibilityand
disease severity in zoonotic H1N1 and H5N1 infections, the
data available suggest that host immunogenetic variation
could play an important role in determining the outcome
of the immune response. With improvements in surveillance
and case conﬁrmation as well as new sequencing and
gene expression platforms, we now have the capability to
study host genetic variants among severe respiratory ill-
ness cases. Although several challenges to conducting such
a study include ethical permission to carry out genetic
polymorphism studies, the need for large numbers of well-
characterised clinical specimens with relevant clinical data,
diﬃculty to obtain suﬃcient number of samples from severe
and fatal cases at a single institution, and diﬃculty in
identifying mild controls. The extreme cases of human
H5N1 disease are very rare, sporadic, with scattered cases in
diﬀerent countries, adding economic and political sensitivi-
ties associated with this disease. Overcoming these barriers
and conducting collaborative research can lead to insights
that will shed light on the varying degree of susceptibility
observed between populations during the recent H1N1
pandemic and will provide greater insight into the host-
pathogen interactions that determine disease course during
severe H5N1 infection.
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